Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
NCT03738228
Active Not Recruiting
This phase I trial studies how well atezolizumab before and/or with standard of care chemoradiotherapy works in immune system activation in patients with stage IB2, II, IIIB, or IVA cervical cancer that has spread to the lymph nodes. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab before and/or with chemoradiotherapy may lower the chance o... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +15 locations
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Cervical Squamous Cell Carcinoma
Register for Updates
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
NCT05839119
Recruiting
This study is for patients who have bladder cancer that invades into the muscle wall of the bladder. The standard treatment for patients with muscle invasive bladder cancer is to give 4 cycles of chemotherapy with the drugs cisplatin and gemcitabine, then to do an operation to remove the bladder (cystectomy). In this study, the investigators will test participants' bladder cancer to see if their bladder cancer has a receptor for testosterone inside the bladder cancer cells. If it has the testos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Lifespan Cancer Institute, Providence, Rhode Island
Conditions: Urothelial Carcinoma Bladder, Androgen Receptor Positive
Register for Updates
BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer
NCT03527264
Terminated
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of the investigational drug in combination with radiation to learn whether the drug(s) works in treating a specific disease. In this study, researchers are studying three treatment arms, each using standard chemotherapy, with the drug cisplatin and radiation and the drug Nivolumab. Each treatment Arm will test the addition of Nivolumab at a different time point
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Rhode Island Hospital, Providence, Rhode Island +1 locations
Conditions: Cervical Cancer
Register for Updates
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
NCT06717243
Recruiting
The goal of this observational study is to understand how genomic and epigenetic factors contribute to resistance against chemo-immunotherapy in adults diagnosed with extensive-stage small cell lung cancer (ES-SCLC) or metastatic large cell neuroendocrine carcinoma (LCNEC). Both ES-SCLC and LCNEC are aggressive forms of lung cancer with limited treatment options and poor prognosis. While initial responses to chemo-immunotherapy are often promising, most patients develop resistance within a few m... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/18/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York +1 locations
Conditions: Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood, Biomarkers, Immunotherapy
Register for Updates
A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.
NCT05137067
Completed
This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.
Gender:
ALL
Ages:
Between 25 years and 75 years
Trial Updated:
03/18/2025
Locations: Optimal Health Research, Salt Lake City, Utah
Conditions: Breast Cancer, Lung Cancer, Prostate Cancer
Register for Updates
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
NCT04030455
Active Not Recruiting
This phase II trial studies how well cisplatin, docetaxel, and pembrolizumab work in treating patients with stage II-III laryngeal cancer. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8
Register for Updates
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
NCT04832854
Completed
This study will evaluate the surgical safety and feasibility of atezolizumab plus tiragolumab alone or in combination with platinum-based chemotherapy as neoadjuvant treatment for participants with previously untreated locally advanced non-small cell lung cancer (NSCLC). The study will also evaluate the efficacy, pharmacokinetics, immunogenicity, and safety of atezolizumab plus tiragolumab alone or in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by adjuvant ate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: City of Hope Cancer Center, Duarte, California +21 locations
Conditions: Non-Small Cell Lung Cancer (NSCLC)
Register for Updates
Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery
NCT04169763
Recruiting
This phase I trial studies the side effects and best dose of nelfinavir when given together with cisplatin and external beam radiation therapy in treating patients with vulvar cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery. Nelfinavir is an antiviral drug normally used to treat human immunodeficiency virus (HIV). Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8
Register for Updates
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
NCT02595424
Active Not Recruiting
This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, capecitabine, cisplatin, carboplatin and etoposide, work in different ways to stop the growth of tumor cells,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Kingman Regional Medical Center, Kingman, Arizona +672 locations
Conditions: Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
Register for Updates
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
NCT04379596
Recruiting
DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expressing advanced/metastatic gastric/gastroesophageal junction (GEJ) and esophageal adenocarcinoma patients. Study hypotheses: Combination of T-DXd with cytotoxic chemotherapy and/or immunotherapy administered to subjects at the recommended phase 2 dose will sho... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/14/2025
Locations: Research Site, Santa Monica, California +99 locations
Conditions: Gastric Cancer
Register for Updates
A Study of GSK5764227 in Participants With Advanced Solid Tumors
NCT06551142
Recruiting
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: GSK Investigational Site, Denver, Colorado +13 locations
Conditions: Neoplasms
Register for Updates
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
NCT03965234
Recruiting
This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreadin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Metastatic Bone Sarcoma, Metastatic Malignant Neoplasm in the Lung, Metastatic Soft Tissue Sarcoma, Metastatic Unresectable Sarcoma, Resectable Sarcoma, Colorectal Cancer
Register for Updates